Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up.

  title={Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up.},
  author={Lori L. Altshuler and Trisha Suppes and David O. Black and Willem A. Nolen and Paul E. Keck and Mark A. Frye and Susan L. McElroy and Ralph W Kupka and Heinz Grunze and Jörg Walden and Gabrielle S Leverich and Kirk D. Denicoff and David A. Luckenbaugh and Robert M. Post},
  journal={The American journal of psychiatry},
  volume={160 7},
OBJECTIVE While guidelines for treating patients with bipolar depression recommend discontinuing antidepressants within 6 months after remission, few studies have assessed the implications of this strategy on the risk for depressive relapse. This study examined the effect of antidepressant discontinuation or continuation on depressive relapse risk among bipolar subjects successfully treated for an acute depressive episode. METHOD Eighty-four subjects with bipolar disorder who achieved… 

Figures and Tables from this paper

Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study.

Patients who achieve a positive acute antidepressant response to 10 weeks of antidepressant treatment adjunctive to a mood stabilizer will probably maintain response with the same continued treatment, and are less likely to further improve when the same treatment is sustained.

Treatment response and duration of maintenance treatment with adjunctive antidepressants in bipolar depression: A retrospective chart review

Bipolar depression has heterogeneous treatment responses to adjunctive antidepressant and antidepressants should be discontinued within 8 weeks after improvement to euthymia to minimize the risk of manic switching.

Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD.

In bipolar depression accompanied by manic symptoms, antidepressants do not hasten time to recovery relative to treatment with mood stabilizers alone, and treatment with antidepressants may lead to greater manic symptom severity.

Treatment of bipolar depression

Depressive symptoms and episodes dominate the long-term course of bipolar disorder and are associated with high levels of disability and an increased risk of suicide. However, the treatment of

Antidepressants have complex associations with longitudinal depressive burden in bipolar disorder.

Overview of antidepressant treatment of bipolar depression.

Overall efficacy was significantly greater with antidepressants than with placebo-treatment and not less than was found in trials for unipolar major depression, and risks of non-spontaneous mood-switching specifically associated with antidepressant treatment are less than appears to be widely believed.

Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients.

That the number of antidepressant trials, but not duration of antidepressant treatment, was associated with prospective nonresponse suggests that it is the repeated use of antidepressants to treat episodes of depression that is related to poor prospective response to naturalistic treatment.

The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review.

It is suggested that antidepressant discontinuation may increase the risk of depressive relapse in some patients with bipolar disorder.

Discontinuing Antidepressant Treatment in Major Depression

Compared with patients whose antidepressants were discontinued, those with continued treatment showed much lower relapse rates, and differences in relapses off versus on antidepressants fell markedly with longer follow‐up, but gradual discontinuation (dose‐tapering or use of long‐acting agents) did not yield lower relapse rate.

Risk of recurrence following discontinuation of lithium treatment in bipolar disorder.

Risk of early recurrence of bipolar illness, especially of mania, evidently is increased following discontinuation of lithium use and may exceed that predicted by the course of the untreated disorder.

Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications.

Recurrences increased sharply soon after discontinuing lithium, but were markedly limited and not merely delayed, by slow discontinuation; post-discontinuation relapse risk has implications for the design, management, and interpretation of protocols involving discontinuation of long-term treatments that should be considered in both clinical management and research.

Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers.

In bipolar patients with breakthrough major depressive episodes despite ongoing adequately-dosed mood stabilizer medication, switches into hypomania or mania occurred in 14% of the acute phases and 33%" of the continuation phases.

Antidepressant discontinuation-related mania: critical prospective observation and theoretical implications in bipolar disorder.

These 6 cases suggest a paradoxical effect whereby antidepressant discontinuation actually induces mania in spite of adequate concomitant mood-stabilizing treatment.

Bipolar depression and antidepressant-induced mania: a naturalistic study.

The frequency and severity of postdepressive mood elevation associated with acute or continuation antidepressant therapy may be reduced by mood stabilizers, which may be more likely in patients with a strong history of mania.

Bipolar depression: treatment options.

Mood stabilizers, lithium in particular, are recommended as the first-line treatment and addition of a second mood stabilizer or a cyclic antidepressant would be an appropriate next step.

Response to maintenance therapy in bipolar illness. Effect of index episode.

An interaction between treatment and the nature of the index episode (the episode that brought the patients into the study) was found and both lithium and the combination were superior to imipramine.